Plexxikon
Scaffold-Based Drug Discovery
Cardio-Renal
CNS
Inflammation
Metabolic Disease
Oncology
About
Management
Pipeline
Cardio-Renal
CNS
Inflammation
Metabolic Disease
Oncology
Clinical Trials
Partners
News
Press Releases
Press Kit
Careers
Contact Us
Driving Directions
Press Releases
Recent Press Releases
06/05/2011
Plexxikon Reports Positive Data from Phase 3 and Phase 2 Trials of Vemurafenib (PLX4032)
06/02/2011
Plexxikon Announces Combination Trials for Vemurafenib in Melanoma
05/18/2011
Plexxikon Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at ASCO 2011 Annual Meeting
05/10/2011
New Drug Applications Submitted for Vemurafenib Market Approval in Melanoma
04/04/2011
Daiichi Sankyo Completes Plexxikon Acquisition
03/08/2011
Plexxikon Initiates Phase 2 Clinical Trial in Hodgkin Lymphoma with PLX3397
02/28/2011
Daiichi Sankyo To Acquire Plexxikon
01/27/2011
Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622
01/18/2011
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
01/06/2011
Plexxikon Signs Agreement with Genentech to Co-Promote PLX4032 in the US
Archived Press Releases